Download Full eBooks in PDF
Reimbursement And Access To Prescription Drugs Under Medicare Part B Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Reimbursement And Access To Prescription Drugs Under Medicare Part B book. This book definitely worth reading, it is an incredibly well-written.
Author : Anonim
Publisher : Unknown
Page : 100 pages
File Size : 51,9 Mb
Release : 2003
Category : Electronic
ISBN : UOM:39015090417984
Author : United States. Congress. Senate. Committee on Finance. Subcommittee on Health Care
Publisher : Unknown
Page : 100 pages
File Size : 48,7 Mb
Release : 2002
Category : Medical
ISBN : PURD:32754074745344
Author : Anonim
Publisher : Unknown
Page : 60 pages
File Size : 43,7 Mb
Release : 2024-06-03
Category : Health insurance
ISBN : UOM:39015022573201
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Publisher : National Academies Press
Page : 235 pages
File Size : 46,9 Mb
Release : 2018-03-01
Category : Medical
ISBN : 9780309468084
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
Publisher : National Academies Press
Page : 442 pages
File Size : 42,7 Mb
Release : 2011-04-03
Category : Medical
ISBN : 9780309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : Anonim
Publisher : Unknown
Page : 234 pages
File Size : 54,6 Mb
Release : 2000
Category : Drugs
ISBN : STANFORD:36105028431273
On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).
Author : Institute of Medicine,Committee on Routine Patient Care Costs in Clinical Trials for Medicare Beneficiaries
Publisher : National Academies Press
Page : 86 pages
File Size : 48,6 Mb
Release : 2000-03-17
Category : Medical
ISBN : 9780309068888
Increasingly over the past five years, uncertainty about reimbursement for routine patient care has been suspected as contributing to problems enrolling people in clinical trials. Clinical trial investigators cannot guarantee that Medicare will pay for the care required, and they must disclose this uncertainty to potential participants during the informed consent process. Since Medicare does not routinely "preauthorize" care (as do many commercial insurers) the uncertainty cannot be dispelled in advance. Thus, patients considering whether to enter trials must assume that they may have to pay bills that Medicare rejects simply because they have enrolled in the trial. This report recommends an explicit policy for reimbursement of routine patient care costs in clinical trials. It further recommends that HCFA provide additional support for selected clinical trials, and that the government support the establishment of a national clinical trials registry. These policies (1) should assure that beneficiaries would not be denied coverage merely because they have volunteered to participate in a clinical trial; and (2) would not impose excessive administrative burdens on HCFA, its fiscal intermediaries and carriers, or investigators, providers, or participants in clinical trials. Explicit rules would have the added benefit of increasing the uniformity of reimbursement decisions made by Medicare fiscal intermediaries and carriers in different parts of the country. Greater uniformity would, in turn, decrease the uncertainty about reimbursement when providers and patients embark on a clinical trial.
Author : F. Randy Vogenberg
Publisher : ASHP
Page : 169 pages
File Size : 43,8 Mb
Release : 2006
Category : Business & Economics
ISBN : 9781585281084
As a health system pharmacist dealing with health care reform initiatives and accountable care organizations, it is important to have a fundamental understanding of health care reimbursement that has a focus on pharmacy. Understanding Pharmacy Reimbursement is the essential resource that allows you to more effectively deal with the rapidly changing and constantly emerging reimbursement issues over the next few years.
Author : United States. Health Care Financing Administration
Publisher : Unknown
Page : 6 pages
File Size : 46,5 Mb
Release : 1993
Category : Hospice care
ISBN : MINN:31951D01035074B
Author : Anonim
Publisher : Unknown
Page : 20 pages
File Size : 48,9 Mb
Release : 1990
Category : Income tax deductions for medical expenses
ISBN : MINN:30000001753056
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Board on Health Care Services
Publisher : National Academies Press
Page : 103 pages
File Size : 43,8 Mb
Release : 2020-01-27
Category : Medical
ISBN : 9780309498517
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Author : Anonim
Publisher : World Health Organization
Page : 70 pages
File Size : 48,8 Mb
Release : 2020-09-29
Category : Business & Economics
ISBN : 9789240011878
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
Author : United States. Congress. Senate. Committee on Finance
Publisher : Unknown
Page : 68 pages
File Size : 49,6 Mb
Release : 2003
Category : Electronic
ISBN : STANFORD:36105050312185
Author : United States. Task Force on Prescription Drugs
Publisher : Unknown
Page : 228 pages
File Size : 49,6 Mb
Release : 1968
Category : Insurance, Pharmaceutical services
ISBN : UOM:39015072109450
Author : United States. Congress. Senate. Committee on Finance
Publisher : Createspace Independent Publishing Platform
Page : 102 pages
File Size : 41,6 Mb
Release : 2017
Category : Law
ISBN : IND:30000159042237
Examining the proposed Medicare part B drug demonstration : hearing before the Committee on Finance, United States Senate, One Hundred Fourteenth Congress, second session, June 28, 2016.